• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Zymeworks Inc. (Amendment)

    2/14/23 9:32:24 AM ET
    $ZYME
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ZYME alert in real time by email
    SC 13G/A 1 doc1.htm Schedule 13G/A


     
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
    SCHEDULE 13G/A
     
     
    Under the Securities Exchange Act of 1934
    (Amendment No. 01)*
     
    Zymeworks Inc. 

    (Name of Issuer)
     
    Common Stock

    (Title of Class of Securities)
     
    98985W102

    (CUSIP Number)
     
    December 31, 2022

    (Date of Event Which Requires Filing of this Statement)
     
    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
     
         ⌧ Rule 13d-1(b)
     
         □ Rule 13d-1(c)
     
         □ Rule 13d-1(d)
     
    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
     
    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
     


     
     

     
     
    CUSIP No.  98985W102            
     
          
    1   NAMES OF REPORTING PERSONS
    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
     BANK OF AMERICA CORPORATION
    56-0906609
       
    2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

      (a)   □
      (b)   ⌧
       
    3 SEC USE ONLY
      
      
       
    4 CITIZENSHIP OR PLACE OF ORGANIZATION
      
     Delaware
        
    NUMBER OF SHARES BENEFICIALLY  OWNED BY EACH REPORTING PERSON WITH:  5   SOLE VOTING POWER
      
     0
       
    6 SHARED VOTING POWER
      
     0
       
    7 SOLE DISPOSITIVE POWER
      
     0
       
    8 SHARED DISPOSITIVE POWER
      
     0
       
    9   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
      
     0
       
    10   CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
      
     □
       
    11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
      
     0.0 %
       
    12 TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
      
     HC
     
    FOOTNOTES
      
     
     
     

     
     
    Item 1.

     
    (a)
    Name of Issuer
     
     
    Zymeworks Inc.

     
    (b)
    Address of Issuer’s Principal Executive Offices
     
     
    540-1385 WEST 8TH AVENUE
    VANCOUVER, A1 V6H 3V9

    Item 2.

     
    (a)
    Name of Person Filing
     
     
    BANK OF AMERICA CORPORATION

     
    (b)
    Address of Principal Business Office or, if none, Residence
     
     
    BANK OF AMERICA CORPORATE CENTER
    100 N TRYON ST
    CHARLOTTE, NC 28255

     
    (c)
    Citizenship
     
     
    Delaware

     
    (d)
    Title of Class of Securities
     
     
    Common Stock

     
    (e)
    CUSIP Number
     
     
    98985W102

     
    Item 3.
    If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     
    (a)
    □
    Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).

     
    (b)
    □
    Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).

     
    (c)
    □
    Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).

     
    (d)
    □
    Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8).

     
    (e)
    □
    An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);

     
    (f)
    □
    An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);

     
    (g)
    ⌧
    A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);

     
    (h)
    □
    A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

     
    (i)
    □
    A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

     
    (j)
    □
    A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J).

     
    (k)
    □
    A group, in accordance with § 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:

     
     
     

     
     
    Item 4.
    Ownership.
     
    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

     
    (a)
    Amount beneficially owned: 0

     
    (b)
    Percent of class: 0.0 %

     
    (c)
    Number of shares as to which the person has:

     
    (i)
    Sole power to vote or to direct the vote: 0

     
    (ii)
    Shared power to vote or to direct the vote: 0

     
    (iii)
    Sole power to dispose or to direct the disposition of: 0

     
    (iv)
    Shared power to dispose or to direct the disposition of: 0

    Item 5.
    Ownership of Five Percent or Less of a Class
     
    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ⌧.
     
    Ownership is 0.0%
     
    Item 6.
    Ownership of More than Five Percent on Behalf of Another Person.
     
    Not Applicable
     
    Item 7.
    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company
     
    Not Applicable
     
    Item 8.
    Identification and Classification of Members of the Group
     
    Not Applicable
     
    Item 9.
    Notice of Dissolution of Group
     
    Not Applicable
     
     
     

     
     
     
    Item 10.
    Certification
      
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.
     
     

    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
     
     
     BANK OF AMERICA CORPORATION 
        
    Date: February 10, 2023
    By:
    /s/  Andres Ortiz  
        Andres Ortiz  
        Title:  Authorized Signatory  
        
     
    Footnotes:
    Attention:
    Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001)
     
     

    Get the next $ZYME alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $ZYME

    DatePrice TargetRatingAnalyst
    5/20/2025Buy
    TD Cowen
    12/16/2024$18.00Neutral → Overweight
    Analyst
    11/7/2024$10.00 → $25.00Market Perform → Outperform
    Leerink Partners
    11/1/2024$12.00Overweight → Equal Weight
    Wells Fargo
    3/21/2023$12.00Overweight
    Wells Fargo
    1/4/2023$10.00 → $8.00Neutral
    H.C. Wainwright
    12/20/2022$7.70 → $11.00Hold → Buy
    Jefferies
    11/1/2022$40.00 → $8.00Buy → Neutral
    H.C. Wainwright
    More analyst ratings

    $ZYME
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Zymeworks Announces NMPA Approval of Zanidatamab in China for Adults with Previously Treated, Unresectable or Metastatic HER2-high expression (IHC3+) Biliary Tract Cancer

      Zanidatamab is the first and only dual HER2-targeted bispecific antibody approved for HER2+ biliary tract cancer in China; conditional approval based on the results of the HERIZON-BTC-01 clinical study$20 million milestone payment to be received from BeOne Medicines; Zymeworks remains eligible to receive up to $144 million in additional development and commercial milestones VANCOUVER, British Columbia, May 30, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (NASDAQ:ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, inflammation, and autoimmune dise

      5/30/25 6:00:00 AM ET
      $ZYME
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Zymeworks Announces Presentations Highlighting Breadth of Oncology Portfolio at Upcoming Medical Conferences

      Partner presentations reinforce ability of proprietary Azymetric™ platform to develop clinically validated therapeutic antibodiesLong-term outcomes and survival data for Ziihera® (zanidatamab-hrii), which was developed using Azymetric™, to be presented at ASCO and highlight its potential to transform the treatment landscape for first-line HER2-positive gastroesophageal cancerZW171 Trial-in-Progress (TiP) poster at ASCO, ZW191 TiP poster at ESMO Gynaecological Cancers Congress; trial enrollment remains on track VANCOUVER, British Columbia, May 22, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (NASDAQ:ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunct

      5/22/25 5:00:00 PM ET
      $ZYME
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Zymeworks Announces Participation in Upcoming Investor Conferences

      VANCOUVER, British Columbia, May 21, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (NASDAQ:ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, inflammation, and autoimmune disease, today announced that management will participate in the following upcoming investor conferences: Jefferies Global Healthcare Conference: Zymeworks' management will participate in one-on-one meetings and a fireside chat on June 4 at 2:35 pm Eastern Time (ET) in New York, NY.Goldman Sachs Global Healthcare Conference: Zymeworks' management will participate in one-on-one

      5/21/25 6:00:00 AM ET
      $ZYME
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ZYME
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Ecor1 Capital, Llc exercised 5,086,480 in-the-money shares at a strike of $0.00 and covered exercise/tax liability with 41 shares (SEC Form 4)

      4 - Zymeworks Inc. (0001937653) (Issuer)

      6/27/25 5:50:21 PM ET
      $ZYME
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Ecor1 Capital, Llc bought $635,586 worth of shares (55,421 units at $11.47) (SEC Form 4)

      4 - Zymeworks Inc. (0001937653) (Issuer)

      5/19/25 6:35:05 PM ET
      $ZYME
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Ecor1 Capital, Llc bought $1,456,408 worth of shares (128,713 units at $11.32) (SEC Form 4)

      4 - Zymeworks Inc. (0001937653) (Issuer)

      4/18/25 3:17:11 PM ET
      $ZYME
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ZYME
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • TD Cowen initiated coverage on Zymeworks

      TD Cowen initiated coverage of Zymeworks with a rating of Buy

      5/20/25 8:13:34 AM ET
      $ZYME
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Zymeworks upgraded by Analyst with a new price target

      Analyst upgraded Zymeworks from Neutral to Overweight and set a new price target of $18.00

      12/16/24 6:40:30 AM ET
      $ZYME
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Zymeworks upgraded by Leerink Partners with a new price target

      Leerink Partners upgraded Zymeworks from Market Perform to Outperform and set a new price target of $25.00 from $10.00 previously

      11/7/24 6:47:25 AM ET
      $ZYME
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ZYME
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Ecor1 Capital, Llc bought $635,586 worth of shares (55,421 units at $11.47) (SEC Form 4)

      4 - Zymeworks Inc. (0001937653) (Issuer)

      5/19/25 6:35:05 PM ET
      $ZYME
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Ecor1 Capital, Llc bought $1,456,408 worth of shares (128,713 units at $11.32) (SEC Form 4)

      4 - Zymeworks Inc. (0001937653) (Issuer)

      4/18/25 3:17:11 PM ET
      $ZYME
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Ecor1 Capital, Llc bought $3,623,970 worth of shares (317,208 units at $11.42) (SEC Form 4)

      4 - Zymeworks Inc. (0001937653) (Issuer)

      4/7/25 6:34:11 PM ET
      $ZYME
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ZYME
    SEC Filings

    See more
    • SEC Form SCHEDULE 13D filed by Zymeworks Inc.

      SCHEDULE 13D - Zymeworks Inc. (0001937653) (Subject)

      6/27/25 6:14:18 PM ET
      $ZYME
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 8-K filed by Zymeworks Inc.

      8-K - Zymeworks Inc. (0001937653) (Filer)

      6/27/25 4:15:34 PM ET
      $ZYME
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Zymeworks Inc. filed SEC Form 8-K: Regulation FD Disclosure

      8-K - Zymeworks Inc. (0001937653) (Filer)

      5/30/25 5:14:06 PM ET
      $ZYME
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ZYME
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Zymeworks Inc.

      SC 13G/A - Zymeworks Inc. (0001937653) (Subject)

      11/14/24 9:00:57 PM ET
      $ZYME
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Zymeworks Inc.

      SC 13G/A - Zymeworks Inc. (0001937653) (Subject)

      11/14/24 4:27:20 PM ET
      $ZYME
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Zymeworks Inc.

      SC 13G - Zymeworks Inc. (0001937653) (Subject)

      11/13/24 4:30:24 PM ET
      $ZYME
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ZYME
    Leadership Updates

    Live Leadership Updates

    See more
    • Zymeworks Appoints Dr. Sabeen Mekan as Senior Vice President, Clinical Development

      VANCOUVER, British Columbia, April 21, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (NASDAQ:ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, inflammation, and autoimmune disease, today announced that Sabeen Mekan, M.D., has been appointed as Senior Vice President, Clinical Development. Reporting directly to the Chief Executive Officer, Dr. Mekan will have a key role in formulating the clinical development strategy for Zymeworks' clinical-stage oncology portfolio, including global regulatory affairs. Dr. Jeff Smith, who joined Zymeworks in 2023,

      4/21/25 6:00:00 AM ET
      $ZYME
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Zymeworks Announces Appointment of Oleg Nodelman to Board of Directors

      VANCOUVER, British Columbia, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (NASDAQ:ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, inflammation, and autoimmune disease, today announced the appointment of Oleg Nodelman to its board of directors, effective February 17, 2025. Mr. Nodelman is the Founder and Managing Director of EcoR1 Capital, LLC, a biotech-focused investment advisory firm, which invests in companies at all stages of research and development. With a proven track record in investment management gained over more than two de

      2/18/25 6:00:00 AM ET
      $ZYME
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Augurex Life Sciences Corp. Names Healthcare Leader Neil Klompas to Succeed Co-Founder Dr. Norma Biln as President and CEO

      Veteran life sciences executive Mr. Neil Klompas to assume role of President and CEO Co-Founder and outgoing CEO Dr. Norma Biln to helm research and new product development and remain Chair of the Board of Directors Augurex Life Sciences Corp., a world leader in the early diagnosis of autoimmune diseases and a pioneer in the field of 14-3-3η based diagnostics, today announced the appointment of Mr. Neil Klompas as President and Chief Executive Officer. Mr. Klompas will succeed Augurex's Co-founder Dr. Norma Biln, who has served as President and CEO since the Company began operations in 2008. Dr. Biln will continue to be an integral part of the company transitioning into the interim r

      8/6/24 7:00:00 AM ET
      $ZYME
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ZYME
    Financials

    Live finance-specific insights

    See more
    • Zymeworks Provides Corporate Update and Reports First Quarter 2025 Financial Results

      Six posters presented at the American Association for Cancer Research (AACR) annual meetingAppointment of Dr. Sabeen Mekan as Senior Vice President, Clinical DevelopmentReported $321.6 million in cash resources as of March 31, 2025 (compared to $324.2 million as of December 31, 2024), which when combined with certain anticipated regulatory milestone payments, provides a projected cash runway into 2H-2027Will host conference call with management today at 4:30 p.m. Eastern Time (ET) VANCOUVER, British Columbia, May 08, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (NASDAQ:ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to imp

      5/8/25 4:05:00 PM ET
      $ZYME
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Zymeworks to Report First Quarter 2025 Financial Results and Host Conference Call on May 8, 2025

      VANCOUVER, British Columbia, April 17, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (NASDAQ:ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, inflammation, and autoimmune disease, today announced that management will report its first quarter 2025 financial results after market close on May 8, 2025. Following the announcement, management will host a conference call and webcast to discuss financial results and provide a corporate update on May 8, 2025 at 4:30 pm Eastern Time. The event will be webcast live with dial-in details and webcast replay

      4/17/25 6:00:00 AM ET
      $ZYME
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Zymeworks Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results

      First-in-human global studies initiated for ZW191, an antibody-drug conjugate (ADC) engineered to target folate receptor-⍺ (FR⍺) and ZW171, a bispecific 2 + 1 T cell engager (TCE) targeting mesothelinAcceleration of the planned investigational new drug (IND) application to mid-2025 for ZW251, an ADC engineered to target glypican-3 (GPC3) U.S. Food and Drug Administration (FDA) granted accelerated approval of Ziihera® (zanidatamab-hrii) for the treatment of adults with previously-treated, unresectable or metastatic HER2-positive (HER2+) (IHC 3+) second-line biliary tract cancer (BTC)Reported $324.2 million in cash resources as of December 31, 2024, which when combined with certain anticipated

      3/5/25 4:05:00 PM ET
      $ZYME
      Biotechnology: Pharmaceutical Preparations
      Health Care